Bessemer Group
CPRX

Bessemer Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Bessemer Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.29M Sell
136,606
-2,345
-2% -$69.2K 0.01% 622
2026
Q1 		$3.44M Buy
138,951
+304
+0.2% +$7.24K 0.01% 625
2025
Q4 		$3.24M Buy
138,647
+135,161
+3,877% +$3.01M 0.01% 617
2025
Q3 		$69K Buy
3,486
+2,678
+331% +$55.1K ﹤0.01% 1352
2025
Q2 		$18K Buy
808
+275
+52% +$6.49K ﹤0.01% 1595
2025
Q1 		$13K Buy
533
+100
+23% +$2.25K ﹤0.01% 1669
2024
Q4 		$9K Buy
433
+204
+89% +$4.38K ﹤0.01% 1796
2024
Q3 		$5K Buy
229
+122
+114% +$2.26K ﹤0.01% 1904
2024
Q2 		$2K Hold
107
– – ﹤0.01% 1930
2024
Q1 		$2K Hold
107
– – ﹤0.01% 1930
2023
Q4 		$2K Hold
107
– – ﹤0.01% 2012
2023
Q3 		$1K Hold
107
– – ﹤0.01% 2061
2023
Q2 		$1K Buy
+107
New +$1.54K ﹤0.01% 2134

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bessemer Group's CPRX Position: Q2 2026 in Review

Bessemer Group reduced its Catalyst Pharmaceutical (CPRX) stake by 1.7% in Q2 2026, selling an estimated $69.2K and leaving 136,606 shares worth $4.29M. The position accounts for 0.01% of the portfolio, ranked #622.

Bessemer Group first reported a position in CPRX in Q2 2023 and has held it in 13 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Bessemer Group held 136,606 shares of Catalyst Pharmaceutical worth $4.29M as of Q2 2026.
  • Bessemer Group sold 2,345 Catalyst Pharmaceutical shares in Q2 2026, an estimated $69.2K.
  • Catalyst Pharmaceutical made up 0.01% of Bessemer Group's portfolio in Q2 2026, its #622 holding.
  • Bessemer Group first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 13 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.